271 related articles for article (PubMed ID: 26980022)
41. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
42. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
[TBL] [Abstract][Full Text] [Related]
43. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
[TBL] [Abstract][Full Text] [Related]
44. The role of microRNAs in intrahepatic cholangiocarcinoma.
Li Z; Shen J; Chan MT; Wu WK
J Cell Mol Med; 2017 Jan; 21(1):177-184. PubMed ID: 27619971
[TBL] [Abstract][Full Text] [Related]
45. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
46. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
47. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.
Xie N; Cai JB; Zhang L; Zhang PF; Shen YH; Yang X; Lu JC; Gao DM; Kang Q; Liu LX; Zhang C; Huang XY; Zou H; Zhang XY; Song ZJ; Sun HX; Fu BM; Ke AW; Shi GM
Cell Death Dis; 2017 Dec; 8(12):3205. PubMed ID: 29235470
[TBL] [Abstract][Full Text] [Related]
48. Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Zhu YJ; Xu Q; Shao MY; Cao XY; Wu ZR; Chen YW; Bu H; Shi YJ
Hepatobiliary Pancreat Dis Int; 2019 Oct; 18(5):464-470. PubMed ID: 31402267
[TBL] [Abstract][Full Text] [Related]
49. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
50. Co‑expression of the carbamoyl‑phosphate synthase 1 gene and its long non‑coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma.
Ma SL; Li AJ; Hu ZY; Shang FS; Wu MC
Mol Med Rep; 2015 Dec; 12(6):7915-26. PubMed ID: 26499888
[TBL] [Abstract][Full Text] [Related]
51. 14-3-3σ downregulation suppresses ICC metastasis via impairing migration, invasion, and anoikis resistance of ICC cells.
Yang Z; Jin Q; Hu W; Dai L; Xue Z; Man D; Zhou L; Xie H; Wu J; Zheng S
Cancer Biomark; 2017 Jul; 19(3):313-325. PubMed ID: 28482619
[TBL] [Abstract][Full Text] [Related]
52. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.
Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390
[TBL] [Abstract][Full Text] [Related]
53. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
54. IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma.
Gao Y; Yang M; Jiang Z; Woda BA; Mercurio AM; Qin J; Huang X; Zhang F
Hum Pathol; 2014 Jun; 45(6):1184-91. PubMed ID: 24745619
[TBL] [Abstract][Full Text] [Related]
55. Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma?
Cheng Z; Lei Z; Shen F
Cancer Lett; 2019 Sep; 460():10-17. PubMed ID: 31212000
[TBL] [Abstract][Full Text] [Related]
56. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.
Zhao Z; Ma J; Wu K; Chen L; Yu J; Hu W; Zhang K
Clin Transl Oncol; 2016 Sep; 18(9):878-83. PubMed ID: 26563145
[TBL] [Abstract][Full Text] [Related]
57. Role of eIF3C Overexpression in Predicting Prognosis of Intrahepatic Cholangiocarcinoma.
Xu YP; Dong ZN; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Huang XY; Guo CY
Dig Dis Sci; 2022 Feb; 67(2):559-568. PubMed ID: 33576946
[TBL] [Abstract][Full Text] [Related]
58. CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma.
Qi Y; Wang D; Huang W; Wang B; Huang D; Xiong F; Chen X; Chen Y
J Exp Clin Cancer Res; 2019 Oct; 38(1):413. PubMed ID: 31590696
[TBL] [Abstract][Full Text] [Related]
59. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
[TBL] [Abstract][Full Text] [Related]
60. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.
Schmitz KJ; Lang H; Wohlschlaeger J; Reis H; Sotiropoulos GC; Schmid KW; Baba HA
Virchows Arch; 2007 Feb; 450(2):135-41. PubMed ID: 17165088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
